Back | Next |
home / stock / blrx / blrx message board
Subject | By | Source | When |
---|---|---|---|
The gaining last trade up | midastouch017 | investorshub | 04/22/2023 8:55:54 PM |
$BLRX The now up | midastouch017 | investorshub | 04/20/2023 2:14:26 PM |
$BLRX Price trading | midastouch017 | investorshub | 04/19/2023 11:49:41 AM |
$BLRX MomentumIts trading last up | midastouch017 | investorshub | 04/19/2023 1:47:29 AM |
I have been in $BLRX since 2019. | midastouch017 | investorshub | 04/18/2023 4:10:29 PM |
$BLRX has a new National Sales Director | jcon777 | investorshub | 04/18/2023 3:15:24 PM |
Welcome Spidey. | jcon777 | investorshub | 04/18/2023 3:08:29 PM |
Adding Aphexda helps to collect more stem cells | midastouch017 | investorshub | 04/18/2023 5:21:50 AM |
Excellent news and sp remains stagnant? | midastouch017 | investorshub | 04/17/2023 4:20:39 PM |
BioLineRx Announces Publication in Nature Medicine of its | midastouch017 | investorshub | 04/17/2023 3:51:03 PM |
Additionally, given they are above the 1USD price | midastouch017 | investorshub | 04/13/2023 4:54:59 PM |
BioLineRx Medical Affairs Team at ASFA Congress | midastouch017 | investorshub | 04/13/2023 4:52:13 PM |
1.1400+0.0800 (+7.55%) | midastouch017 | investorshub | 04/11/2023 3:49:31 PM |
I haven't put in a large sum | midastouch017 | investorshub | 04/11/2023 5:44:00 AM |
Indeed, I was looking to get to May 1st | Spideyboy | investorshub | 04/11/2023 5:31:56 AM |
Today will be day 2 of 10. | midastouch017 | investorshub | 04/11/2023 5:15:52 AM |
Just joined the party. | midastouch017 | investorshub | 04/11/2023 5:12:26 AM |
Heck, I don't know what's going on with | Spideyboy | investorshub | 04/11/2023 3:57:05 AM |
Day 1 of 10 | BarrellofHay | investorshub | 04/10/2023 7:52:56 PM |
BioLine RX ($BLRX) | midastouch017 | investorshub | 04/10/2023 9:16:17 AM |
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Ltd. Company Name:
BLRX Stock Symbol:
NASDAQ Market:
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting PR Newswire TEL AVIV, Israel , April 17, 2024 /PRNewswire/ --...
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement PR Newswire - Proceeds to be used to further accelerate uptake of APHEXDA® in stem cell mobilization, life-cycle expansion activities in sic...
BioLineRx Announces $6 Million Registered Direct Offering PR Newswire TEL AVIV, Israel , April 1, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing t...